CryoBalloon Ablation for Treatment of Duodenal Adenomas
| 대상 질환 | Duodenal Adenomas, Familial Adenomatous Polyposis |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | Johns Hopkins University |
| 상태 | 완료 |
| 참여자 수 | 33 명 |
| 중재(약물) | CryoBalloon ablation |
| 시작일 | 2019년 5월 13일 |
| 완료일 | 2025년 6월 1일 |
| 결과 공개일 | 2026년 8월 4일 |
요약
This multicenter prospective non-randomized interventional study (clinical trial) that will assess the safety and efficacy of cryoballoon ablation treatment using the C2 Cryoballoon device (Pentax Medical Corporation) as an alternative primary treatment modality for sporadic and familial nonampullary nonpolypoid (flat) duodenal adenomas.
Safety of CryoBalloon Ablation in Treating Non-ampullary Non-polypoid Duodenal Adenomas (DAs) as Assessed by Participants With Adverse Events
| Individuals With Duodenal Adenomas | 12 Participants |
|---|
Participants With Complete Eradication of DA
| Individuals With Duodenal Adenomas | 23 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 — National Cancer Institute (NCI)